Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Panel Discusses Details of NIP for Shingles Jabs, OKs Inclusion of Prevenar 20
July 19, 2024
- Lilly’s Alzheimer’s Med Up for Health Ministry Panel Review on August 1
July 19, 2024
- MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
- Chuikyo OKs Plan for Drug Price Survey in FY2024
July 18, 2024
- Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo
July 18, 2024
- Label Revisions Ordered for Opdivo, Yervoy, Duvroq, and More
July 18, 2024
- LDP Lawmakers Call for Expanded Budget for Pharma Innovation, Stable Supplies
July 18, 2024
- MHLW Clarifies Criteria for “Medical Necessity” of LLPs before Elective Care Rollout
July 17, 2024
- Pharma Innovation, Supply Raised as Key Topics for FY2025 Budget: LDP Confab
July 10, 2024
- Japan Wants to Spur Regulatory Use of RWD, but Still Puts Weight on RCTs
July 10, 2024
- Ex-Health Minister Otsuji to Retire from Politics Next Summer
July 10, 2024
- PMDA to Push Simultaneous Development of Pediatric Drugs via New Consultation Center
July 9, 2024
- LDP Group Renews Call for Gender-Neutral HPV Vaccination
July 9, 2024
- MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
July 8, 2024
- Breyanzi’s Label Expansion Up for MHLW Panel Review on July 19
July 8, 2024
- Panelists Wary of Proposed Switch of Generic GMP Inspection Authority to PMDA
July 8, 2024
- Minister Nudges Generic Product Consolidation, Pitches “5 Makers per API”
July 5, 2024
- LDP Veteran Seiichi Eto to Bow Out from Politics Next Summer
July 5, 2024
- Payer Chides AnGes’s Course Change on Collategene, Urges Re-Think of System’s Set-Up
July 4, 2024
- Over 60% of Generic Firms Carry Jointly Developed Products, 98% of Espha Drugs Fall into This Category
July 3, 2024
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…